IC
ADMA icon

Ikarian Capital’s ADMA Biologics ADMA Stock Holding History

Ikarian Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-234,854
Closed -$4.28M – 162
2025
Q4 		$4.28M Buy
234,854
+75,000
+47% +$1.26M 0.33% 69
2025
Q3 		$2.34M Buy
+159,854
New +$2.74M 0.24% 92
2020
Q4 		– Sell
-200,000
Closed -$478K – 231
2020
Q3 		$478K Sell
200,000
-178,574
-47% -$490K 0.03% 143
2020
Q2 		$1.11M Sell
378,574
-251,426
-40% -$722K 0.09% 120
2020
Q1 		$1.81M Buy
+630,000
New +$2.18M 0.14% 99

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Ikarian Capital's ADMA Position: Q1 2026 in Review

Ikarian Capital sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 234,854 shares — an estimated $4.28M sold.

Ikarian Capital first reported a position in ADMA in Q1 2020 and held it in 5 quarters. The position peaked at $4.28M in Q4 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Ikarian Capital reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 234,854 ADMA Biologics shares in Q1 2026, an estimated $4.28M.
  • Ikarian Capital first reported a position in ADMA Biologics in Q1 2020 and held it in 5 quarters.
  • Ikarian Capital's ADMA Biologics position peaked at $4.28M in Q4 2025.
  • 357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.